1. Home
  2. |Insights
  3. |Are You Cyber Secure Under the DFARS Rule?

Are You Cyber Secure Under the DFARS Rule?

Client Alert | 1 min read | 09.17.14

With a revised regulatory regime still rippling through the defense industry, DoD fundamentally reshaped the cybersecurity rules in the DoD Federal Acquisition Regulation Supplement in November 2013 by (1) imposing 51 mandatory security controls for DoD-controlled technical information; (2) requiring the DFARS "Safeguarding" clause in all DoD contracts and solicitations; (3) mandating that contractors flow down the requirements, even to commercial subcontractors; and (4) defining detailed reporting requirements for certain types of security  "incidents" or breaches. In a "View from Crowell & Moring: Getting Ahead of the DFARS Safeguarding Rule" published in Bloomberg BNA’s Federal Contracts Report, David Bodenheimer, Evan Wolff, and Kate Growley discuss the definitional gaps, compliance pitfalls, and practical pointers for determining the reach of the DFARS Safeguarding Rule, the mandate for "adequate security," the scope of the reporting requirements, and the emerging lessons learned in navigating these game-changing cybersecurity safeguards governing DoD procurements.


Contacts

Insights

Client Alert | 9 min read | 10.21.26

Artificial Intelligence in Life Sciences: Reliability of AI-Generated Evidence in Drug Discovery and Development

The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .  ...